Point-of-care testing shows clinically relevant variation in the degree of inhibition of platelets by standard-dose abciximab therapy during percutaneous coronary intervention

Options for accessing this content:

• If you have access to this content through a society membership, please first log in to your society website.
• If you would like institutional access to this content, please recommend the title to your librarian.
• Login via Athens http://onlinelibrary.wiley.com/athens or other institutional login options http://onlinelibrary.wiley.com/login-options .
• You can purchase online access to this Article for a 24-hour period (price varies by title)
  • If you already have a Wiley Online Library or Wiley InterScience user account: login above and proceed to purchase the article.
  • New Users: Please register, then proceed to purchase the article.

Registered Users please login:

• Access your saved publications, articles and searches
• Manage your email alerts, orders and subscriptions
• Change your contact information, including your password

E-mail:

Password:

Please register to:

• Save publications, articles and searches
• Get email alerts
• Get all the benefits mentioned below!

Register now >